Was ist Zolpidem?
Zolpidem is a non-benzodiazepine hypnotic medicine — commonly referred to as a Z-drug — used for the short-term treatment of insomnia, particularly where difficulty falling asleep is the primary complaint. It is available under several brand names across Europe, including Stilnoct and Sanval.
Zolpidem belongs to the imidazopyridine chemical class but shares a similar mechanism of action with benzodiazepines, acting on GABA-A receptors. However, its receptor subtype selectivity is considered to confer a somewhat different pharmacological profile, including comparatively less muscle relaxation and anxiolysis compared to classical benzodiazepines.
Wie wirkt Zolpidem work?
Zolpidem selectively enhances the activity of gamma-aminobutyric acid (GABA) at the GABA-A receptor complex by binding preferentially to the alpha-1 subunit. This receptor subtype is associated with sedation and hypnosis, which explains why zolpidem’s primary effects are sleep-promoting with relatively less muscle relaxation and anti-anxiety activity compared to classical benzodiazepines.
The result is:
- Reduced sleep onset latency: Patients fall asleep faster
- Increased total sleep time: Particularly in the earlier part of the night
- Minimal disruption to sleep architecture: Zolpidem is considered to preserve normal sleep stages better than some longer-acting hypnotics
Zolpidem has a short half-life of approximately 2.4 hours (slightly longer in older adults and women), which is designed to allow sleep onset without excessive next-morning sedation.
Für wen ist Zolpidem for?
Zolpidem is indicated for the short-term treatment of insomnia in adults. It is particularly suited to sleep onset insomnia (difficulty falling asleep) rather than sleep maintenance insomnia (waking during the night), given its relatively short duration of action.
Clinical guidelines consistently recommend non-pharmacological interventions — in particular, Cognitive Behavioural Therapy for Insomnia (CBT-I) — as the primary treatment for chronic insomnia. Zolpidem and other hypnotics are recommended only where:
- CBT-I is unavailable or has been inadequate
- The insomnia is acute and significantly impairing functioning
- There is a clear short-term indication
Zolpidem is not appropriate for:
- People with sleep apnoea syndrome
- Those with myasthenia gravis or severe respiratory insufficiency
- People with significant liver impairment
- Those with a history of alcohol or substance dependence
- Pregnant or breastfeeding women
Dosierung
Zolpidem is taken orally as a tablet, immediately before going to bed. A full 7–8 hours of sleep should be available before any activities requiring alertness.
| Group | Recommended Dose | Notes |
|---|---|---|
| Adult women | 5 mg at bedtime | Lower dose due to slower clearance |
| Adult men | 5–10 mg at bedtime | May increase to 10 mg if 5 mg insufficient |
| Adults over 65 | 5 mg at bedtime | Start low; increased sensitivity |
| Maximum recommended duration | 2–4 weeks | Including tapering period |
The EMA updated its guidance on zolpidem dosing to recommend that women start at 5 mg due to evidence of higher morning blood concentrations and associated driving impairment risk.
Nebenwirkungen
Common Nebenwirkungen (may affect more than 1 in 10 people)
- Drowsiness or somnolence the following day
- Headache
- Dizziness
- Nausea
- Anterograde amnesia (difficulty forming new memories after taking the medicine)
Serious risks
- Complex sleep behaviours: Sleep-walking, sleep-driving, sleep-eating with no memory of events — risk is higher at doses above recommended levels and when combined with alcohol or CNS depressants
- Next-morning impairment: Driving impairment may persist into the morning even after a full night’s sleep, particularly in women, older adults, or those taking higher doses
- Dependence and withdrawal: Particularly with use beyond the recommended treatment period
- Rebound insomnia: Temporary worsening of sleep upon stopping treatment
- Hallucinations and psychiatric reactions: Including confusion, agitation, and hallucinations, particularly in older adults
- Falls: Due to sedation and impaired coordination during the night
Zolpidem vs im Vergleich zu Alternativen
| Medicine | Class | Primary Indication | Half-Life | Rx Required |
|---|---|---|---|---|
| Zolpidem | Z-drug | Sleep onset insomnia | ~2–3 hours | Yes |
| Zopiclone | Z-drug | Sleep onset and maintenance | ~5–6 hours | Yes |
| Lormetazepam | Benzodiazepine | Severe insomnia | ~10–12 hours | Yes |
| Melatonin | Hormone | Circadian disruption, jet lag | ~1–2 hours | Low dose: No |
| Diphenhydramine | Antihistamine | Occasional mild insomnia | ~9 hours | No |
Zopiclone may offer an advantage over zolpidem for patients with both sleep onset and sleep maintenance difficulties, given its longer half-life. A doctor is best placed to determine which option is most clinically appropriate for individual patients.
How to access sleep treatment online in Europe
Zolpidem is a prescription-only controlled medicine across all EU member states. It cannot be legally dispensed without a valid prescription from a licensed medical professional.
Prescrivia operates as a technology intermediary: our platform connects patients with independent EU-registered doctors who can conduct confidential online health assessments. We do not prescribe medicines, employ doctors, or dispense medicines directly.
The process is:
- Complete a health assessment: Provide a structured health history, including details of your sleep difficulties, current medications, and relevant medical history.
- Doctor review: An independent EU-registered doctor reviews your assessment. If a prescription sleep medicine is clinically appropriate, they may issue a prescription.
- Prescription and fulfilment: If a prescription is issued, it is forwarded to a licensed EU pharmacy partner for dispensing and delivery.
Important: Prescrivia does not guarantee that a prescription will be issued. All clinical decisions are made independently by qualified medical professionals.
Wichtige Sicherheitsinformationen
Do not take Zolpidem if you have:
- Sleep apnoea syndrome
- Myasthenia gravis
- Severe respiratory insufficiency or liver disease
- A history of alcohol or drug dependence
Driving and machinery: Do not drive, cycle, or operate machinery after taking zolpidem. Morning impairment may persist into the following day, particularly in women and older adults. The EMA warns that zolpidem blood concentrations can remain above levels that impair driving ability for 7–8 hours after a 10 mg dose.
Alcohol: Never combine zolpidem with alcohol — the combination significantly enhances sedation and substantially increases the risk of complex sleep behaviours.
Quellen
Medical information on this page is based on the following sources:
- European Medicines Agency (EMA). Questions and answers on zolpidem-containing medicines. EMA/CHMP/742257/2013.
- European Medicines Agency (EMA). Assessment report on zolpidem. EMEA/H/A-31/1401.
- World Health Organization (WHO). Management of sleep disorders — WHO guidelines. who.int
This content is reviewed periodically to reflect updated clinical guidance. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.
Frequently asked questions
- What is Zolpidem used for?
- Zolpidem is a sedative-hypnotic medicine (Z-drug) prescribed for the short-term treatment of insomnia characterised by difficulty falling asleep (sleep onset insomnia). It is a prescription-only medicine across all EU member states and is intended for use over a maximum of 2–4 weeks.
- How quickly does Zolpidem work?
- Zolpidem is rapidly absorbed after oral administration, reaching peak plasma concentrations within approximately 30–120 minutes. Most patients experience sleep onset within 30 minutes of taking it. It should only be taken immediately before going to bed.
- What are the risks of complex sleep behaviours with Zolpidem?
- Zolpidem has been associated with sleep-related complex behaviours including sleep-walking, sleep-driving, sleep-eating, and making phone calls while asleep, with no memory of the events. These are more likely at higher doses or when zolpidem is combined with alcohol or other CNS depressants. Patients who experience any of these behaviours should stop zolpidem and contact their doctor immediately.
- Can Zolpidem cause dependence?
- Yes. Like other hypnotic medicines, zolpidem carries a risk of tolerance and physical and psychological dependence, particularly with use beyond the recommended 2–4 week period. Rebound insomnia (worsening sleep after stopping) and withdrawal symptoms can occur on discontinuation. Dose tapering under medical guidance is recommended.
- Is there a lower dose for women?
- Yes. The EMA has recommended that women receive a lower starting dose of zolpidem (5 mg rather than 10 mg) because women clear the drug from their bodies more slowly than men, leading to higher blood concentrations in the morning and a greater risk of impaired driving. Your doctor will determine the appropriate dose for you.
Behandlungen
Prescrivia ist ausschließlich eine Vermittlungsplattform. Wir erbringen keine medizinischen Leistungen, verschreiben keine Behandlungen und geben keine Medikamente ab. Alle medizinischen Entscheidungen werden von unabhängigen, in der EU registrierten Ärzten getroffen. Alle Medikamente werden von lizenzierten EU-Apotheken abgegeben. Diese Plattform erleichtert die Verbindung zwischen Patienten und Gesundheitsdienstleistern.